Valneva (NASDAQ:VALN) Shares Up 2.3% – Here’s Why

Shares of Valneva SE (NASDAQ:VALN) traded up 2.3% during trading on Friday . The stock traded as high as $7.45 and last traded at $7.42. 6,542 shares traded hands during trading, a decline of 75% from the average session volume of 25,882 shares. The stock had previously closed at $7.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Valneva in a research report on Friday.

Valneva Price Performance

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company’s fifty day moving average is $6.34 and its two-hundred day moving average is $5.59. The stock has a market cap of $582.64 million, a price-to-earnings ratio of -55.15 and a beta of 1.93.

Valneva (NASDAQ:VALN) last posted its earnings results on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. As a group, research analysts predict that Valneva SE will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA purchased a new position in Valneva SE (NASDAQ:VALN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.